Indication
Cablivi is indicated for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.
Loading your page…
Loading your page…
Purpura, Thrombotic Thrombocytopenic
Marketing Authorisation Holder: Ablynx NV
EMA Authorisation: 30/08/2018
INN: caplacizumab
AI Drug & Interaction Analysis
Free account required
Ask Osler about Cablivi: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.